Undisclosed Research Target 2
Rare Cardiomyopathy
ResearchUndisclosed
Key Facts
About Atrium Therapeutics
Atrium Therapeutics is a private biotech company focused on transforming the standard of care for cardiac diseases by addressing their underlying genetic causes. The company launched with approximately $270 million in funding and leverages a proprietary RNA delivery platform, derived from Avidity Biosciences' AOC technology, to enable targeted oligonucleotide therapy for the heart. Its initial pipeline targets rare, life-threatening cardiomyopathies with high unmet need, positioning it as a leader in the emerging field of precision cardiology.
View full company profileTherapeutic Areas
Other Rare Cardiomyopathy Drugs
| Drug | Company | Phase |
|---|---|---|
| Undisclosed Research Target 1 | Atrium Therapeutics | Research |